Dapagliflozin protects neural and vascular dysfunction of the retina in diabetes

INTRODUCTION: Dapagliflozin, a sodium-glucose transporter inhibitor, effectively reduces blood glucose and is indicated for individuals with kidney diseases and cardiovascular disorders. In this study, we further expand the therapeutic benefit of dapagliflozin in the neural and vascular retina, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Qianyi, Leley, Sameer P, Bello, Erika, Dhami, Hurshdeep, Mathew, Deepa, Bhatwadekar, Ashay Dilip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Pathophysiology/Complications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114950/
https://www.ncbi.nlm.nih.gov/pubmed/35577387
http://dx.doi.org/10.1136/bmjdrc-2022-002801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114950/
https://www.ncbi.nlm.nih.gov/pubmed/35577387
http://dx.doi.org/10.1136/bmjdrc-2022-002801

Ejemplares similares